

susceptible to a primary infection) women of reproductive age in a population and the rate of ALL in the population.

Since women at risk for JV virus infection that might result in ALL in their child during pregnancy are those who have not yet had a primary infection, methods to achieve immunization are disclosed in the application. Since immunization could be specifically targeted to women who have never been exposed to JC virus, the application also discloses methods of screening women for prior exposure to the virus. In addition, methods for diagnosis of susceptibility are disclosed which can be applied to cord blood samples which may allow identification of children at high risk and allow early intervention. These methods of screening can be performed using either serological or molecular methods of analysis and both types are claimed in the application.

#### **raf Protein Kinase Therapeutics**

U Rapp, H App, SM Storm (NCI)  
Serial No. 08/207,954 filed 18 Mar 94  
(priority to 23 Aug 91)  
*Licensing Contact:* Ken Hemby, 301/  
496-7735 ext. 265.

Novel *raf* protein kinases may be valuable for the treatment of cancers. *raf* protein kinases are enzyme that stimulate cell growth in a variety of cell systems and, when expressed in specifically altered forms, can initiate malignant cell growth. These novel *raf* protein kinases, which are mutant constructs or are transcribed from *raf* antisense DNA, can be used to inhibit the activity of cellular *raf* protein kinases and prevent or reverse malignant cell growth. Other potential areas of application include proliferation diseases such as psoriasis and restenosis, and inflammatory diseases.

This research has been described in *Trends in Biochem. Sci.* 19: 474-480, 1994.

*Main advantages of invention:* *raf* is by now a verified cancer target; *raf* directed drugs promise to be widely applicable and nontoxic based on clinical studies with antisense ODN.

*Stage of development:* Ready to be used for drug screens, application in gene therapy. Further development required: Use of inhibitory *raf* mutants in gene therapy requires clinical studies.

Dated: October 21, 1997.

**Barbara M. McGarey,**

*Deputy Director, Office of Technology Transfer.*

[FR Doc. 97-28623 Filed 10-28-97; 8:45 am]

BILLING CODE 4140-01-M

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of Allergy and Infectious Diseases; Notice of Meeting: Board of Scientific Counselors**

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Board of Scientific Counselors, National Institute of Allergy and Infectious Diseases, at 8 a.m. on December 8-10, 1997, National Institutes of Health, Building 10, Rooms 433 and 413, 9000 Rockville Pike, Bethesda, Maryland.

In accordance with the provisions set forth in Section 552b(c)(6), Title 5, U.S.C. and Section 10(d) of Public Law 92-463, the entire meeting will be closed to the public for the review, discussion, and evaluation of individual programs and projects by the National Institutes of Health, including consideration of personal qualifications and performing, the competence of individual investigators, and similar items, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Dr. Thomas J. Kindt, Executive Secretary, Board of Scientific Counselors, NIAID, NIH, Building 10, Room 4A31, telephone 301-496-3006, will provide substantive program information.

(Catalog of Federal Domestic Assistance Program No. 93-301, National Institutes of Health)

Dated: October 21, 1997.

**LaVerne Y. Stringfield,**

*Committee Management Officer, NIH.*

[FR Doc. 97-28626 Filed 10-28-97; 8:45 am]

BILLING CODE 4140-01-M

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **Center for Scientific Review; Notice of Closed Meetings**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Center for Scientific Review Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Behavioral and Neurosciences.

*Date:* November 14, 1997.

*Time:* 9:00 a.m.

*Place:* Capitol Holiday Inn, Washington, DC.

*Contact Person:* Dr. Sam Rawlings, Scientific Review Administrator, 6701 Rockledge Drive, Room 5160, Bethesda, Maryland 20892, (301) 435-1243.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* November 18, 1997.

*Time:* 12:00 p.m.

*Place:* Holiday Inn-National Airport, Crystal City, VA.

*Contact Person:* Dr. Gerald Liddel, Scientific Review Administrator, 6701 Rockledge Drive, Room 4186, Bethesda, Maryland 20892, (301) 435-1150.

*Purpose/Agenda:* To review Small Business Innovation Research.

*Name of SEP:* Behavioral and Neurosciences.

*Date:* November 7, 1997.

*Time:* 9:00 a.m.

*Place:* Capitol Holiday Inn, Washington, DC.

*Contact Person:* Dr. Sam Rawlings, Scientific Review Administrator, 6701 Rockledge Drive, Room 5160, Bethesda, Maryland 20892 (301) 435-1243.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* November 20, 1997.

*Time:* 8:30 a.m.

*Place:* Doubletree Hotel, Rockville, MD.

*Contact Person:* Dr. Michael Micklin, Scientific Review Administrator, 6701 Rockledge Drive, Room 5198, Bethesda, Maryland 20892, (301) 435-1258.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* November 24, 1997.

*Time:* 8:00 a.m.

*Place:* Ramada Inn, Rockville, MD.

*Contact Person:* Dr. Abubakar Shaikh, Scientific Review Administrator, 6701 Rockledge Drive, Room 6166, Bethesda, Maryland 20892, (301) 435-1042.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93-837-93.844, 93.846-93.878, 93.892, 93-893, National Institutes of Health, HHS)

Dated: October 22, 1997.

**LaVerne Y. Stringfield,**

*Committee Management Officer, NIH.*

[FR Doc. 97-28625 Filed 10-28-97; 8:45 am]

BILLING CODE 4140-01-M